Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Chronic hepatitis B remains a significant global health concern.
• Interferon-based therapies have been explored for hepatitis B virus (HBV) treatment.
• Optimizing treatment regimens for improved efficacy and safety is crucial.

Purpose of the Study:

• To compare the efficacy and safety of alpha-interferon monotherapy versus a combination of alpha- and gamma-interferon in chronic hepatitis B patients.
• To evaluate viral DNA and HBeAg negativization rates.
• To assess the tolerability of the combined interferon regimen.

Main Methods:

• A randomized study involving 32 chronic hepatitis B patients.
• Group 1: 16 patients received alpha-interferon (10 MU/m2) thrice weekly for 4 months.
• Group 2: 16 patients received alpha-interferon (10 MU/m2) plus gamma-interferon (2 MU/m2) simultaneously.

Main Results:

• Hepatitis B virus DNA negativity was observed in 50% of the alpha-interferon group versus 25% in the combination group.
• Hepatitis B e antigen negativization rates were 31% for alpha-interferon and 19% for the combination therapy.
• The combination therapy exhibited poor tolerance and potential liver decompensation.

Conclusions:

• Alpha-interferon monotherapy demonstrated superior efficacy compared to the combination of alpha- and gamma-interferon at the doses studied.
• The combination therapy did not yield better outcomes and was associated with significant safety concerns.
• Further research should focus on optimizing interferon dosages or exploring alternative therapeutic strategies for chronic hepatitis B.